The European Group for Blood and Marrow Transplantation has recently run a prospective, randomized trial comparing an early (3 months) vs a late (9 months) immunization program after allo-SCT with three doses of the conjugate 7-valent pneumococcal vaccine. This trial has shown that the response rate assessed 1 month after the third dose of conjugate vaccine was not inferior after an early vaccination vs a late vaccination. Part of the responder cohort of these patients (n ¼ 28) were chosen to assess the functionality of the anti-pneumococcal antibodies through an opsonophagocytic assay, 1 month after the third dose of conjugate vaccine. We have assessed the relationship between IgG titers measured by the pneumococcal ELISA and functional titers measured by opsonophagocytic assay of anti-pneumococcal antibodies. We found a significant correlation between titers for both assays, and conclude that the response to PCV7 after SCT induces functional antibodies. Bone Marrow Transplantation (2010Transplantation ( ) 45, 1423Transplantation ( -1426 doi:10.1038/bmt.2009 Because pneumococcal infection may occur before 6 months, 1 the EBMT has run a prospective trial (IDWP01) to compare the immune response after an early vs a latestarting at 3 or at 9 months after transplant-immunization with three doses of PCV7. We showed that the pneumococcal IgG ELISA response rate 1 month after three PCV7 doses was not lower in the early group (45/57; 79%) than in the late group (47/57; 82%): the 90% CI for the difference was À3.5% (À15.6, 8.6), which was well above the À20% non-inferiority criterion.
Introduction
Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at increased risk of Streptococcus pneumoniae invasive infection, around 20 times more than the normal population. 1 This event can be prevented by immunoglobulins or by active immunization. Both the polysaccharide 23-valent vaccine (PPV23) and the 7-valent conjugate vaccine (PCV7) have been assessed after HSCT. The immune response to the PPV23 is suboptimal during the first year after transplant, and even later in the case of chronic GVHD or immunosuppressive drugs. 2 The PCV7 is more immunogenic than the polysaccharide vaccine, both in infants 3 and in HSCT recipients 4 and has been evaluated in adults 5 and pediatric transplant recipients. 6 Because pneumococcal infection may occur before 6 months, 1 the EBMT has run a prospective trial (IDWP01) to compare the immune response after an early vs a latestarting at 3 or at 9 months after transplant-immunization with three doses of PCV7. We showed that the pneumococcal IgG ELISA response rate 1 month after three PCV7 doses was not lower in the early group (45/57; 79%) than in the late group (47/57; 82%): the 90% CI for the difference was À3.5% (À15.6, 8.6), which was well above the À20% non-inferiority criterion. 7 However, although antipolysaccharide-specific Ab levels measured by ELISA are the main parameter used to measure the vaccine-induced protection, they may not fully reflect the functional ability of the antibodies to kill S. pneumoniae in vivo, especially in immunocompromised patients. As opsonocytophagotytosis is essential in the host defense against S. pneumoniae, 8 the use of an in vitro opsonophagocytic assay (OPA) is recommended as a secondary end point in pneumococcal vaccine trials. 9 One of the secondary end points of the IDWP01 trial was to assess the OPA of the sera collected from randomly chosen responders. We report here the results of the OPA assays in a cohort of 28 HSCT recipients of the IDWP01 trial. Serum samples were chosen at random among the responders 1 month after the third dose of PCV7. OPA titers were determined as well as the correlation between pneumococcal IgG ELISA and OPA titers.
Materials and methods
The IDWP01 trial was a randomized, non-inferiority trial conducted at 13 EBMT centers, including 158 HSCT recipients from December 2001 to 2004. 7 The primary end point was the proportion of patients with Ab titers X0.15 mg/ml to all seven PCV7 serotypes 1 month after the third dose of vaccine. Patients, aged 5-65 years, were randomized at day 100 after transplant, to be immunized either from 3 or from 9 months after transplant.
From the 102 responders 1 month after the third dose of PCV7, 40 patients (20 in each group) were randomly chosen to be assessed for OPA titers. Of them, there was not enough serum for two patients to perform the test. In addition, as antibacterial use could affect the OPA titers, 10 were excluded from the analysis because they were receiving antibacterials at the time of serum sampling. Finally, 28 patients (14 in the early group and 14 in the late group) who were not receiving antibacterials at the time of serum sampling, were analyzed.
Serum collection and Ab measurements
Venous blood samples were obtained using standard methods and sera were immediately frozen at À20 1C. Sera were assigned code numbers to blind the laboratory for the treatment arm and shipped frozen by BioInova to the US Wyeth laboratory (Pearl River, NY, USA), then bar-coded and tested by qualified laboratory personnel. Serum pneumococcal IgG responses to the seven vaccine serotypes were determined by the WHO-standardized serotypespecific anti-pneumococcal capsular polysaccharide ELISA using pneumococcal C-polysaccharide and 22F to adsorb non-specific antibodies. 10, 11 Pneumococcal IgG ELISA titers were expressed as mg/ml using the standard reference serum 89-SF.
The OPA titers were assessed for each PCV7 serotype by an OPA assay as previously described. 12 Briefly, heatinactivated human serum samples were serially diluted and incubated with the S. pneumoniae OPA bacterial test strains (B2000 CFU per well) and 12.5% of baby rabbit complement in a 96-well microtitre plate. The plates were shaken for 30 min at 37 1C (opsonization step). Differentiated HL60 cells (effector cells) were then added at a B400:1 effector cell to bacterial cell target ratio and the mixture incubated on a shaker for an additional 45 min at 37 1C. After the second incubation, a 0.9% NaCl solution was added to each well and 10 ml of each well was applied to a blood agar plate, which was incubated overnight at 37 1C with 5% CO 2 . Colonies were counted and OPA titers were calculated as the reciprocal of the serum dilution that causes a 50% reduction of the S pneumoniae CFU compared with the CFU from the control wells containing all reagents except human serum. The lowest titer that could be determined in the OPA was a titer of 8.
Statistical analyses
The pneumococcal IgG ELISA titers were expressed in mg/ ml for each of the seven PCV7 antigens. OPA titers can have values of 8, 16, 32, 64, 128, etc. To compare OPA titers between the early and late groups, the MannWhitney U-test was performed. Correlations between pneumococcal IgG ELISA titer and OPA titers were studied using the Pearson correlation coefficient after a logarithmic transformation of the data. All tests were two-sided. The type I error rate was fixed at 0.05. Statistical analysis was performed with SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Among the 28 patients, the mean age was 37 years (minmax 10-56), the M/F ratio was 14/14. The underlying diseases were acute leukemia in nine, chronic leukemia in 13, myelodysplastic syndrome in three, aplastic anemia in two and lymphoma in one patient, mostly in first CR or chronic phase (61%), and transplanted from a matched related donor (78.5%). Fourteen patients were transplanted with a BM graft and 14 with a peripheral stem cell graft. Six patients experienced acute GVHD disease before the first dose of PCV7 and 12 had chronic GVHD. The mean donor age was 34 years (15-55 years). These clinical characteristics were well balanced between the early and late groups.
Significant functional Ab titers as measured by OPA were induced in all patients after PCV7 immunization. There was no difference in the geometric mean OPA titers (GMT) of the 28 patients for any of the PCV7 serotype when comparing the early and the late groups. Therefore, the data were analyzed by pooling together the patient titers of both groups to determine the correlation between pneumococcal IgG ELISA and OPA titers.
The correlation between OPA titers and the ELISA Ab titers are summarized in Figure 1 . There was a significant correlation between OPA and ELISA titers for all seven PCV7 serotype (Po0.05).
Discussion
The immune response to pneumococcal vaccines, either polysaccharide or conjugate, never reaches 100% responders in HSCT recipients. However, active immunization is the more efficient approach to protect these patients to S. pneumoniae invasive infection. Indeed, rates of antibiotic resistance of S. pneumoniae remain high in Europe, and antibiotic prophylaxis is less and less satisfying over time. PCV7 may induce protective levels of pneumococcalspecific antibodies in 64-82% after three doses given during the first year of transplant.
7,4-6 Therefore, it is now recommended by a consortium of several international organizations for prophylaxis of infections after HSCT, to start pneumococcal immunization with three or four doses of PCV7, from 3-6 months after transplant, and then to complete the series with a PPV23 or a booster PCV7 dose. 13 However, although the Ab levels measured by ELISA are widely used as the primary end point of any pneumococcal vaccine study, the use of additional tests to accurately assess the protective immunity provided by active immunization is highly recommended as a secondary end point of such trials. 9 The best functional measure is likely to be the opsonophagocytic activity as measured by OPA whose results mimic in vitro the host's primary mechanism of protection against pneumococci. 8 The need for additional tests to assess the response is also supported by the uncertainty of the protective titers especially in immunocompromised adults where protective titer levels have not been established. Owing to the delay and impairment of the immune response after HSCT, one may suspect that antibodies produced after vaccination by HSCT recipients may have a suboptimal opsonophagocytic activity. Discrepancies between ELISA results and OPA results have already been found in older children and adult populations, especially in the elderly 14 and in HIV patients. 15 Therefore, OPA data provide important additional information to assess the efficacy of PCV7 in an immunocompromised population such as HSCT patients, even in the absence of an established protective OPA titer cutoff in adults.
Our study shows that in allogeneic HSCT recipients responding to three doses of PCV7 by pneumococcal IgG ELISA, significant functional OPA titers are elicited indicating that this patient population can mount a specific functional Ab response after immunization with PCV7. As also shown by ELISA, no difference was seen in OPA GMTs between the early and late group responders. Finally, there is a significant relationship between the pneumococcal IgG ELISA titers and the OPA titers. This strongly suggests that the immune response to PCV7 is associated with an efficient functional Ab activity, and therefore supports the recommendation of active immunization with pneumococcal vaccines after HSCT.
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